MapLight Therapeutics
Maplight: A biopharmaceutical firm innovating CNS disorder therapeutics via drug discovery platform.
- 67
- Private company
- Redwood City, CA, USUnited States
Maplight: A biopharmaceutical firm innovating CNS disorder therapeutics via drug discovery platform.
maplightrx.comCrawled Oct 16, 2026
Approximately 40% of people with Alzheimer’s disease will experience delusions and hallucinations as part of their diagnosis – this is a condition known as Alzheimer’s disease psychosis. Neuropsychiatric symptoms including psychosis are associated with a worse prognosis and earlier progression to nursing home care, severe dementia and death.
Rapid progress toward targeted improvements for sociability and irritability in children and adults with ASD.
Rapid progress toward precise approach to prevention and treatment of dyskinesia.
Targeting neurons that become dysfunctional without directly blocking dopamine D2 receptors.
First in human study demonstrates positive safety and tolerability profile for MapLight’s M1/M4 muscarinic agonist therapy
MapLight Therapeutics announced completion of a Phase 1 trial evaluating the bioavailability, safety and tolerability of an extended release formulation of ML-007, alone and with a precision-matched muscarinic antagonist.
Dr. Foff Joins MapLight to Help Further Advance the Company’s Portfolio of Novel Therapeutics for Patients with Disorders of the Central Nervous System (CNS).
Hanson Brings 25 Years of Experience Advising Public and Private Companies to MapLight as the New Legal and Compliance Leader
MapLight Therapeutics is a clinical-stage biotech company focused on drug discovery for central nervous system disorders. It uses optogenetics, in vivo physiology and spatial transcriptomics to identify drug targets and develop therapies for psychiatric symptoms.
Dr. Bernard Silverman has more than 20 years of experience in clinical development and team building. Since 2019, he has consulted for biotechnology firms, including as Chief Medical Officer for Lyndra Therapeutics, Nirsum Therapeutics and Nocion Therapeutics.
Dr. Kane chaired psychiatry at The Zucker Hillside Hospital for 34 years and The Donald and Barbara Zucker School of Medicine for 12 years. He is a professor at the school.
Dr. Jaeger has more than 35 years’ experience in neuropsychology and psychopathology. She owns and is president of CognitionMetrics, LLC, a consultancy serving the pharmaceutical industry on clinical programs in CNS disorders.
Biotech company developing effective, safe, circuit-specific treatments to make life better for those with difficult-to-treat brain disorders
Targeted treatment for Autism Spectrum Disorder, Parkinson’s Disease and Schizophrenia.
The notice addresses the collection, use and disclosure of personal data in clinical trials involving patients, caregivers, health care personnel, legally authorized representatives and witnesses.
MapLight Therapeutics secures FDA Fast Track designation for **ML-007C-MA**, its experimental **M1/M4 muscarinic agonist**, targeting hallucinations and delusions in **Alzheimer’s disease psychosis (ADP)**. The drug candidate advances as a potential treatment for a patient population with limited therapeutic options. The designation accelerates clinical development and review for this investigational therapy.
Jan 2026BioSpaceNews article
MapLight Therapeutics has filed a **Form S-1** with the SEC to begin its **initial public offering (IPO)** of **14.75 million shares**. The clinical-stage biopharmaceutical company specializes in treating **central nervous system disorders**. The offering aims to raise capital for further development of its pipeline.
Oct 2025Yahoo FinanceNews article
MapLight Therapeutics begins a Phase 2 trial testing **ML-007C-MA**, a novel **M1/M4 muscarinic agonist**, for treating **Alzheimer’s disease psychosis**. The study assesses the drug’s efficacy, safety, and tolerability in patients. ML-007C-MA targets muscarinic receptors, a pathway linked to cognitive and behavioral symptoms in Alzheimer’s.
Sep 2025PR NewswireNews article
MapLight Therapeutics secures **$372.5 million in Series D funding** to expand its **muscarinic receptor agonist platform**, targeting central nervous system (CNS) drug development. The capital will accelerate research into novel therapies addressing unmet neurological and psychiatric needs. The company’s platform focuses on modulating acetylcholine receptors, a key pathway in cognitive and motor function disorders.
Jul 2025BioXconomyNews article